Luster, Troy A <br/><br/>
Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.  [electronic resource] 

 -  Molecular cancer therapeutics  Feb 2009 
 - 292-302 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1535-7163 
<br/><br/><label>Standard No.: </label>10.1158/1535-7163.MCT-08-0918  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies--pharmacology<br/>Antibodies, Monoclonal--pharmacology<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Boronic Acids--pharmacology<br/>Bortezomib<br/>Carcinoma, Non-Small-Cell Lung--enzymology<br/>Caspases--metabolism<br/>Cell Death--drug effects<br/>Cell Line, Tumor<br/>Death Domain Receptor Signaling Adaptor Proteins--metabolism<br/>Drug Resistance, Neoplasm--drug effects<br/>Drug Screening Assays, Antitumor<br/>Drug Synergism<br/>Enzyme Activation--drug effects<br/>Humans<br/>Lung Neoplasms--enzymology<br/>Pyrazines--pharmacology<br/>Receptors, TNF-Related Apoptosis-Inducing Ligand--immunology